You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,407,793


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,407,793
Title: An aqueous heart preservation and cardioplegia solution
Abstract:A process for preserving a patient\'s organ for transplantation and cardioplegia during cardiac surgery is disclosed which includes harvesting the patient\'s organ for transplantation or arresting the heart during cardiac surgery, perfusing the organ or heart with an aqueous solution, and removing at least a substantial portion of the aqueous solution from the organ or heart to effect the removal of waste products from the organ before transplantation or restarting the heart. The aqueous solutions of these inventions promote anaerobic glycolysis, remove waste products from the organ and maintain the energy production capacity of the organ and are preferably comprised of about 50 to 150 millimoles of histidine per liter of the solution, at least one energy providing material for maintaining the energy production capacity of the organ, about 60 to 90 millimoles of Na.sup.+ per liter of the solution, about 10 to 25 millimoles of K.sup.+ per liter of the solution, and about 3 to 8 millimoles of adenosine per liter of the solution for the transplantation solution and 0.001 to 1 millimoles of adenosine per liter of the solution for cardioplegia. Sodium entry into and depolarization of the cells is resisted by the extracellular to intracellular sodium gradient and use of adenosine. The aqueous solutions of this invention have a pH of about 6.8 to 8.0 where intracellular pH is maintained by the buffering action of the histidine and the solution is preferably used at moderate hypothermia for up to 24 hours.
Inventor(s): Del Nido; Pedro J. (Pittsburgh, PA), Cao-Danh; Hung (Pittsburgh, PA), Sommers; K. Eric (Pittsburgh, PA), Ohkado; Akihiko (Pittsburgh, PA)
Assignee: University of Pittsburgh of the Commonwealth System of Higher Education (Pittsburgh, PA)
Application Number:08/079,315
Patent Claims:1. An aqueous heart preservation solution consisting essentially of:

about 50 to 150 millimoles of histidine per liter of said solution;

at least one energy providing material for maintaining energy production capacity of the organ;

about 20 to 120 millimoles of Na.sup.+ per liter of said solution;

about 5 to 30 millimoles of K.sup.+ per liter of said solution;

about 1 to 10 millimoles of adenosine per liter of said solution;

about 1 to 20 units of regular insulin per liter of said solution: and

about 100 milligrams of lidocaine per liter of said solution wherein said heart preservation solution promotes anaerobic glycolysis, removes waste products from the organ by buffering, maintains the energy production capacity of the organ, and resists sodium entry into the cell during ischemia and reperfusion.

2. The aqueous solution of claim 1, wherein the amount of

said Na.sup.+ is about 60 to 90 millimoles per liter of said solution;

said K.sup.+ is about 10 to 25 millimoles per liter of said solution; and

said adenosine is about 3 to 8 millimoles per liter of said solution.

3. The aqueous solution of claim 2, wherein said solution has a pH of about 6.8 to about 8.0.

4. The aqueous solution of claim 3, wherein said energy providing material comprises about 5 to 20 millimoles of glucose per liter of said solution, whereby anaerobic glycolysis is promoted by use of said glucose.

5. The aqueous solution of claim 3, wherein said energy providing material comprises about 5 to 20 millimoles of fructose per liter of said solution, whereby anaerobic glycolysis is promoted by use of said fructose.

6. The aqueous solution of claim 4, wherein said solution further includes:

about 4 to 16 millimoles of Mg.sup.+2 per liter of said solution;

about 0.05 to 1.0 millimoles of Ca.sup.+2 per liter of said solution;

about 1.0 to 5.0 millimoles of PO.sub.4.sup.-3 per liter of said solution; and

about 10 to 20 millimoles of mannitol per liter of said solution.

7. The aqueous solution of claim 6, wherein the amount of

said Mg.sup.+2 is about 4 to 8 millimoles per liter of said solution;

said Ca.sup.+2 is about 0.05 to 0.4 millimoles per liter of said solution; and

said PO.sub.4.sup.-3 is about 1.25 to 3.0 millimoles per liter of said solution.

8. The aqueous solution of claim 7, wherein said aqueous solution further includes sterile water.

9. The aqueous solution of claim 8, wherein said solution further includes an antiseptic.

10. The aqueous solution of claim 8, wherein said solution further includes an antibiotic.

11. An aqueous cardioplegia solution consisting essentially of:

about 50 to 150 millimoles of histidine per liter of said solution;

at least one energy providing material for maintaining energy production capacity of the heart;

about 20 to 120 millimoles of Na.sup.+ per liter of said solution;

about 5 to 30 millimoles of K.sup.+ per liter of said solution;

about 0.001 to 1 millimole of adenosine per liter of said solution;

about 1 to 20 units of regular insulin per liter of said solution; and

about 100 milligrams of lidocaine per liter of said solution wherein said aqueous solution for cardioplegia promotes anaerobic glycolysis, removes waste products from the organ by buffering, maintains the energy production capacity of the organ, and resists sodium entry into the cell during ischemia and reperfusion.

12. The aqueous solution of claim 11; wherein the amount of

said Na.sup.+ is about 60 to 90 millimoles per liter of said solution; and

said K.sup.+ is about 10 to 25 millimoles per liter of said solution.

13. The aqueous solution of claim 12, wherein said solution has a pH of about 6.8 to about 8.0.

14. The aqueous solution of claim 13, wherein said energy providing material comprises about 5 to 20 millimoles of glucose per liter of said solution, whereby anaerobic glycolysis is promoted by said glucose.

15. The aqueous solution of claim 13, wherein said energy providing material comprises about 5 to 20 millimoles of fructose per liter of said solution, whereby anaerobic glycolysis is promoted by said fructose.

16. The aqueous solution of claim 14, wherein said solution further includes:

about 4 to 16 millimoles of Mg.sup.+2 per liter of said solution;

about 0.05 to 0.4 millimoles of Ca.sup.+2 per liter of said solution;

about 1.0 to 5.0 millimoles of PO.sub.4.sup.-3 per liter of said solution; and

about 10 to 20 millimoles of mannitol per liter of said solution.

17. The aqueous solution of claim 16, wherein the amount of said Mg.sup.+2 is about 4 to 8 millimoles per liter of said solution;

said Ca.sup.+2 is about 0.05 to 0.4 millimoles per liter of said solution; and

said PO.sub.4.sup.-3 is about 1.25 to 3.0 millimoles per liter of said solution.

18. The aqueous solution of claim 16, wherein said aqueous solution further includes sterile water.

19. The aqueous solution of claim 18, wherein said solution further includes an antiseptic.

20. The aqueous solution of claim 18, wherein said solution further includes an antibiotic.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.